AU2002236518A1 - Recombinant anti-CD30 antibodies and uses thereof - Google Patents

Recombinant anti-CD30 antibodies and uses thereof

Info

Publication number
AU2002236518A1
AU2002236518A1 AU2002236518A AU2002236518A AU2002236518A1 AU 2002236518 A1 AU2002236518 A1 AU 2002236518A1 AU 2002236518 A AU2002236518 A AU 2002236518A AU 2002236518 A AU2002236518 A AU 2002236518A AU 2002236518 A1 AU2002236518 A1 AU 2002236518A1
Authority
AU
Australia
Prior art keywords
uses
recombinant anti
cd30 antibodies
cd30
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2002236518A
Other versions
AU2002236518B2 (en
Inventor
Joseph A. Francisco
Grant Risdon
Clay B Siegall
Alan F. Wahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seattle Genetics Inc
Original Assignee
Seattle Genetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US09/724,406 priority Critical patent/US7090843B1/en
Priority to US09/724,406 priority
Application filed by Seattle Genetics, Inc. filed Critical Seattle Genetics, Inc.
Priority to PCT/US2001/044811 priority patent/WO2002043661A2/en
Publication of AU2002236518A1 publication Critical patent/AU2002236518A1/en
Application granted granted Critical
Publication of AU2002236518B2 publication Critical patent/AU2002236518B2/en
Priority claimed from AU2007200173A external-priority patent/AU2007200173B2/en
Application status is Active legal-status Critical
Adjusted expiration legal-status Critical

Links

AU2002236518A 2000-11-28 2001-11-28 Recombinant anti-CD30 antibodies and uses thereof Active 2026-11-28 AU2002236518B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/724,406 US7090843B1 (en) 2000-11-28 2000-11-28 Recombinant anti-CD30 antibodies and uses thereof
US09/724,406 2000-11-28
PCT/US2001/044811 WO2002043661A2 (en) 2000-11-28 2001-11-28 Recombinant anti-cd30 antibodies and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2007200173A AU2007200173B2 (en) 2000-11-28 2007-01-16 Recombinant anti-CD30 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2007200173A Division AU2007200173B2 (en) 2000-11-28 2007-01-16 Recombinant anti-CD30 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
AU2002236518A1 true AU2002236518A1 (en) 2002-08-15
AU2002236518B2 AU2002236518B2 (en) 2006-10-26

Family

ID=24910311

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002236518A Active 2026-11-28 AU2002236518B2 (en) 2000-11-28 2001-11-28 Recombinant anti-CD30 antibodies and uses thereof
AU3651802A Pending AU3651802A (en) 2000-11-28 2001-11-28 Recombinant anti-cd30 antibodies and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU3651802A Pending AU3651802A (en) 2000-11-28 2001-11-28 Recombinant anti-cd30 antibodies and uses thereof

Country Status (12)

Country Link
US (1) US7090843B1 (en)
EP (1) EP1347730B2 (en)
JP (1) JP4303964B2 (en)
AT (1) AT454124T (en)
AU (2) AU2002236518B2 (en)
CA (1) CA2430135C (en)
CY (1) CY1110700T1 (en)
DE (1) DE60141043D1 (en)
DK (1) DK1347730T3 (en)
ES (1) ES2339333T5 (en)
PT (1) PT1347730E (en)
WO (1) WO2002043661A2 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
EP1482972A4 (en) * 2001-11-20 2005-11-23 Seattle Genetics Inc Treatment of immunological disorders using anti-cd30 antibodies
JP2005517674A (en) * 2002-01-03 2005-06-16 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェーVlaams Interuniversitair Instituut Voor Biotechnologie Vzw Novel immunoconjugates useful for tumor treatment
IL162835D0 (en) 2002-01-09 2005-11-20 Medarex Inc Human monoclonal antibodies against cd30
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
DK2357006T3 (en) 2002-07-31 2015-12-21 Seattle Genetics Inc Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
EP2260858B1 (en) 2003-11-06 2016-03-30 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
CA2582016A1 (en) 2004-10-01 2006-04-13 Medarex, Inc. Methods of treating cd30 positive lymphomas
EP1848745B1 (en) 2005-02-18 2014-07-09 Medarex, L.L.C. Monoclonal antibodies against cd30 lacking in fucosyl residues
EP1951757B1 (en) * 2005-10-06 2014-05-14 Xencor, Inc. Optimized anti-cd30 antibodies
WO2008025020A2 (en) * 2006-08-25 2008-02-28 Seattle Genetics, Inc. Cd30 binding agents and uses thereof
RU2511410C2 (en) 2007-07-16 2014-04-10 Дженентек, Инк. ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS FOR USING THEM
WO2009026274A1 (en) 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
KR101641345B1 (en) 2007-10-12 2016-07-20 시애틀 지네틱스, 인크. Combination therapy with antibody-drug conjugates
WO2010027513A2 (en) 2008-09-08 2010-03-11 Psma Development Company, Llc Methods for killing psma-expressing, taxane-resistant cancer cells
US9211319B2 (en) 2009-01-09 2015-12-15 Seattle Genetics, Inc. Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates
KR101224468B1 (en) * 2009-05-20 2013-01-23 주식회사 파멥신 Bispecific antibody having a novel form and use thereof
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
JP6121906B2 (en) 2010-10-22 2017-04-26 シアトル ジェネティクス,インコーポレーテッド Synergistic effect between auristatin antibody drug conjugate and PI3K-AKTmTOR pathway inhibitor
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
HUE039000T2 (en) 2012-10-11 2018-12-28 Daiichi Sankyo Co Ltd Antibody-drug conjugate
JP6272230B2 (en) 2012-10-19 2018-01-31 第一三共株式会社 Antibody-drug conjugate conjugated with a linker containing a hydrophilic structure
EP3564259A2 (en) 2012-11-09 2019-11-06 Innate Pharma Recognition tags for tgase-mediated conjugation
CN105849086B (en) 2012-11-24 2018-07-31 杭州多禧生物科技有限公司 Hydrophily chain junctor and its application on drug molecule and cell-binding molecules conjugation reaction
US9943610B2 (en) 2012-12-21 2018-04-17 Bioalliance C.V. Hydrophilic self-immolative linkers and conjugates thereof
CA2906022A1 (en) 2013-03-15 2014-09-25 Abbvie Inc. Antibody drug conjugate (adc) purification
TW201519903A (en) 2013-03-15 2015-06-01 Abbvie Deutschland Anti-EGFR antibody drug conjugate formulations
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
JP2016528183A (en) 2013-06-21 2016-09-15 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. Enzymatic binding of polypeptides
WO2015113476A1 (en) 2014-01-29 2015-08-06 上海恒瑞医药有限公司 Ligand-cytotoxicity drug conjugate, preparation method therefor, and uses thereof
EP3122757A4 (en) 2014-02-28 2018-02-07 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
EP3119423A2 (en) 2014-03-15 2017-01-25 Novartis AG Treatment of cancer using chimeric antigen receptor
CA2952876A1 (en) 2014-06-20 2015-12-23 Bioalliance C.V. Anti-folate receptor alpha (fra) antibody-drug conjugates and methods of using thereof
EP3160513A1 (en) 2014-06-30 2017-05-03 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US20180044424A1 (en) 2015-02-02 2018-02-15 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
WO2016196344A1 (en) 2015-05-30 2016-12-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
WO2016196935A1 (en) 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
US20180230193A1 (en) 2015-08-07 2018-08-16 Andreas Loew Treatment of cancer using chimeric cd3 receptor proteins
CN108603200A (en) 2015-11-23 2018-09-28 诺华股份有限公司 Lentivirus transfer carrier of optimization and application thereof
JP2019503686A (en) 2016-01-08 2019-02-14 バイオアライアンス セー.フェー. Tetravalent anti-PSGL-1 antibody and use thereof
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
CN110022938A (en) 2016-11-14 2019-07-16 千禧制药公司 The non-adult of 0 antibody drug conjugate of AntiCD3 McAb is administered
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
CN106854245A (en) * 2016-12-28 2017-06-16 无锡傲锐东源生物科技有限公司 Protein monoclonal antibody of AntiCD3 McAb 0 and application thereof
EP3574005A1 (en) 2017-01-26 2019-12-04 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
WO2018158716A1 (en) 2017-03-02 2018-09-07 Cadila Healthcare Limited Novel protein drug conjugate formulation
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
TW201922281A (en) 2017-10-11 2019-06-16 美商西雅圖遺傳學公司 Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy
WO2019084288A1 (en) 2017-10-25 2019-05-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag Antibodies targeting cd32b and methods of use thereof
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
WO2019089870A1 (en) 2017-11-01 2019-05-09 Seattle Genetics, Inc. Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
WO2019183438A1 (en) 2018-03-23 2019-09-26 Seattle Genetics, Inc. Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6909191A (en) 1989-11-20 1991-06-13 Parker, David L. Improved cd-30 antibodies and fragments thereof
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
DE4200043A1 (en) 1991-11-11 1993-05-13 Stein Harald Prof Dr Recombinant CD30 antigen (KI-1) and corresp. nucleic acid - for diagnosis of anaplastic large-cell lymphoma, and for prepn. of antibodies and antisera, in immuno-absorption, etc.
CA2131003A1 (en) 1992-05-26 1993-12-09 Raymond G. Goodwin Novel cytokine that binds cd30
CA2146747C (en) 1992-10-09 2006-12-19 Brian A. Naughton Liver reserve cells
PT678523E (en) 1993-01-14 2004-12-31 Chemo Sero Therapeut Res Inst Anti-hiv recombinant antibodies and their preparation
IL114909A (en) * 1994-08-12 1999-10-28 Immunomedics Inc Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
EP0805871B2 (en) * 1995-01-18 2006-02-22 Boehringer Mannheim Gmbh Anti-cd30 antibodies preventing proteolytic cleavage and release of membrane-bound cd30 antigen
DE19543039C1 (en) 1995-11-08 1996-11-21 Medac Klinische Spezialpraep DNA mols. encoding CD30-specific immunoglobulin variable regions
DE19640733A1 (en) * 1996-10-02 1998-04-09 Abken Hinrich Polypeptide than binds to CD30 without cell activation
EP1283719B1 (en) 2000-04-22 2007-09-05 PharmedArtis GmbH Apoptotic agents
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
EP1482972A4 (en) 2001-11-20 2005-11-23 Seattle Genetics Inc Treatment of immunological disorders using anti-cd30 antibodies

Similar Documents

Publication Publication Date Title
EP1194164B8 (en) Prion protein peptides and uses thereof
HK1058935A1 (en) Cripto blocking antibodies and uses thereof
AU2002248297A1 (en) Aav2 vectors and methods
AU1290001A (en) Antibodies
AU2001252084A1 (en) 3-nitrogen-6,7-dioxygen steroids and uses related thereto
AU2001236073A1 (en) Gene recombinant antibody and its fragment
AU3441400A (en) Peptide
AU6820000A (en) Novel proteases and variants thereof
AU2002249939A1 (en) File switch and switched file system
AU2002331621A1 (en) 2H-phthalazin-1-ones and methods for use thereof
AU2001263456A1 (en) Recombinant bacterial phytases and uses thereof
AU2002311919A1 (en) Specific binding proteins and uses thereof
AU2001289189A1 (en) Scleral clip and procedures for using same
AU2002332290A1 (en) Recombinant anti-osteopontin antibody and use thereof
AU2001243512A1 (en) Heparinase III and uses thereof
AU7358700A (en) Dolastatin peptides
AU2002308562A1 (en) Recombinant tumor specific antibody and use thereof
AU7602400A (en) Secreted proteins and uses thereof
AU3512802A (en) Expression miniarrays and uses thereof
AU2001275445A1 (en) 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
EP1636334A4 (en) Recombinant anti-cd30 antibodies and uses thereof
DE60141043D1 (en) Recombinant anti-cd30 antibodies and their uses
AU2002315389A1 (en) Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
AU2002308515A1 (en) Pentapeptide compounds and uses related thereto
AU2001247616A1 (en) Multivalent antibodies and uses therefor